Edward Woo analyst ASCENDIANT

Currently out of the existing stock ratings of Edward Woo, 303 are a BUY (94.98%), 10 are a HOLD (3.13%), 6 are a SELL (1.88%).

Edward Woo

Work Performance Price Targets & Ratings Chart

Analyst Edward Woo, currently employed at ASCENDIANT, carries an average stock price target met ratio of 42.98% that have a potential upside of 68.35% achieved within 327 days.

Edward Woo’s has documented 560 price targets and ratings displayed on 51 stocks. The coverage is on Healthcare, Communication Services, Consumer Cyclical, Energy, Technology sectors.

Most recent stock forecast was given on GNSS, Genasys at 11-Mar-2026.

Wall Street Analyst Edward Woo

Analyst best performing recommendations are on HSCS (HEART TEST LABORATORIES COMMON STOCK).
The best stock recommendation documented was for BSGM (BIOSIG TECHNOLOGIES, COMMON STOCK) at 4/21/2025. The price target of $2.5 was fulfilled within 22 days with a profit of $1.97 (371.7%) receiving and performance score of 168.95.

Average potential price target upside

ATOS Atossa Genetics ATVI Activision Blizzard BIOL BIOLASE BKNG Booking Holdings EA Electronic Arts ENSV Enservco Co EXPE Expedia Group GME GameStop Corp GNSS Genasys GRPN Groupon JAKK JAKKS Pacific MYO Myomo NBY NovaBay Pharmaceuticals NDRA ENDRA Life Sciences OTLK OUTLOOK THERAPEUTICS INC PCOM Points International Ltd. PHUN Phunware PSTV Plus Therapeutics SINT SINTX Technologies TRIP TripAdvisor TTWO Take-Two Interactive Software TZOO Travelzoo VERB VERB TECHNOLOGY COMPANY INC WISA WiSA Technologies AUTO Autoweb LUCD Lucid Diagnostics IMAC Imac Holdings PAVM PAVmed SURG Surgepays VVOS Vivos Therapeutics  INTZ Intrusion NRXP NRX Pharmaceuticals HSCS Heart Test Laboratories Common Stock AMTX Aemetis SOPA Society Pass RNXT RenovoRx BSGM BioSig Technologies, Common Stock ALZN Alzamend Neuro BLBX Blackboxstocks CING Cingulate COCH Envoy Medical DUOT Duos Technologies Group DXR Daxor GRI GRI Bio AIM AIM ImmunoTech RDHL Redhill Biopharma Ltd AYTU Aytu BioScience ALLR Allarity Therapeutics EVOK Evoke Pharma GHSI Guardion Health Sciences ISR IsoRay

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 17-Sep-2020

$120

$115.28 (2442.37%)

$116.25

3 months 26 days ago
(08-Dec-2025)

2/11 (18.18%)

$108.28 (923.89%)

178

Buy Since 12-Feb-2024

$105

$100.28 (2124.58%)

$105

5 months 27 days ago
(07-Oct-2025)

0/14 (0%)

$89.85 (593.07%)

Buy Since 08-Sep-2023

1 years 9 months 14 days ago
(20-Jun-2024)

1/1 (100%)

$-7.5 (-60.00%)

885

Buy Since 18-Dec-2019

$105

$100.28 (2124.58%)

4 years 9 months 24 days ago
(10-Jun-2021)

4/5 (80%)

$43.95 (71.99%)

266

Show more analysts

Please expand the browser size to see the chart

Which stock is Edward Woo is most bullish on?

Potential upside of $501.33 has been obtained for PAVM (PAVMED)

Which stock is Edward Woo is most reserved on?

Potential downside of -$0 has been obtained for NDRA (ENDRA LIFE SCIENCES)

What Year was the first public recommendation made by Edward Woo?

On 2012

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?